Additionally, given that MAO-B is also a therapeutic target in Parkinson’s disease (PD), we proposed that EF might have potentials as a MAO-B inhibitor to treat PD, which needs further validation in preclinical rodent models of PD. The gene discussed is MAOB; the disease is Parkinson disease.